Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC

This nonrandomized clinical trial evaluates the treatment outcomes and safety of mobocertinib treatment in patients with previously treated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Lascia un commento